Nabriva Therapeutics (NASDAQ:NBRV) Earns Hold Rating from Analysts at StockNews.com
StockNews.com initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research report report published on Monday morning. The brokerage issued a hold rating on the biotechnology company’s stock. Nabriva Therapeutics Price Performance The firm has a market cap of $45.46 million, a price-to-earnings ratio of -0.07 and a beta of 1.53. […]
More Stories
Contrasting Geo Group (NYSE:GEO) & ICF International (NASDAQ:ICFI)
ICF International (NASDAQ:ICFI – Get Free Report) and Geo Group (NYSE:GEO – Get Free Report) are both business services companies,...
UBS Group Initiates Coverage on Summit Therapeutics (NASDAQ:SMMT)
Stock analysts at UBS Group started coverage on shares of Summit Therapeutics (NASDAQ:SMMT – Get Free Report) in a research...
C.H. Robinson Worldwide (NASDAQ:CHRW) Raised to “Outperform” at Wolfe Research
C.H. Robinson Worldwide (NASDAQ:CHRW – Get Free Report) was upgraded by research analysts at Wolfe Research from a “peer perform”...
Omada Health (NASDAQ:OMDA) Now Covered by JPMorgan Chase & Co.
Investment analysts at JPMorgan Chase & Co. began coverage on shares of Omada Health (NASDAQ:OMDA – Get Free Report) in...
Roth Capital Reiterates “Neutral” Rating for Hecla Mining (NYSE:HL)
Hecla Mining (NYSE:HL – Get Free Report)‘s stock had its “neutral” rating restated by stock analysts at Roth Capital in...
INmune Bio’s (INMB) “Neutral” Rating Reiterated at BTIG Research
INmune Bio (NASDAQ:INMB – Get Free Report)‘s stock had its “neutral” rating reiterated by stock analysts at BTIG Research in...